The treatment has been generally well-tolerated, with minor side effects like back pain or nausea reported during infusion. 🧬 Mechanism and Targets
As of early 2026, the program is advancing toward to further evaluate long-term outcomes and safety in larger patient populations. This technology represents a potential shift from chronic disease management to a "one-and-done" therapeutic model for heart health. ATHENA HEART 310
The therapy is being tested for those with severe hypertriglyceridemia (sHTG), mixed dyslipidemia, and familial hypercholesterolemia (HoFH/HeFH). 🚀 Future Outlook The treatment has been generally well-tolerated, with minor
ANGPTL3 is a protein that normally inhibits enzymes that clear lipids from the blood. By "turning off" this gene, the body can more effectively remove fats. The therapy is being tested for those with
Average drops of ~55% at the highest dose, with some patients seeing up to 84% reduction .
Targeted protein levels decreased by an average of 73%.